3 results
Approved WMOCompleted
To evaluate the effect of baricitinib 4-mg QD and background standard-of-care therapy compared with placebo and background standard-of-care therapy on SLE disease activity.
Approved WMOPending
In this study, we look at how safe the new medicinal product XMT-1536 is for the treatment of ovarian cancer and how well it works. We compare the effect of XMT-1536 with the effect of a placebo. A placebo is a product without the active ingredient…
Approved WMOCompleted
The primary objective is to test the hypothesis that baricitinib high dose level in combination with topical corticosteroids (TCS) or baricitinib medium dose level in combination with TCS is superior to placebo in combination with TCS in the…